MK-3120 for Cancer

Recruiting at 19 trial locations

Overseen By Toll Free Number

Age: 18+

Sex: Any

Trial Phase: Phase 1 & 2

Sponsor: Merck Sharp & Dohme LLC

Must be taking: Antiretrovirals, HBV antivirals

Must not be taking: Immunosuppressives, Systemic anticancer

Disqualifiers: Inflammatory bowel, Cardiovascular, CNS metastases, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: Unknown

Duration: Up to approximately 18 months

180 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

Researchers are looking for new ways to treat people with certain advanced solid tumors. Advanced means the cancer has spread to other parts of the body and cannot be removed with surgery. Solid tumors are cancers mostly in body organs and tissues, not in the blood or other body liquids. The main goal of this study is to learn about the safety of MK-3120 and if people tolerate it.

Who Is on the Research Team?

Medical Director

Principal Investigator

Merck Sharp & Dohme LLC

Are You a Good Fit for This Trial?

This trial is for adults with advanced solid tumors that have spread and can't be removed by surgery. Participants must have measurable disease, provide a tumor tissue sample, and have recovered from previous cancer therapy side effects to a manageable level. People with well-controlled HIV on ART, or those who've treated hepatitis B or C are also eligible if they meet certain conditions.

Inclusion Criteria

My advanced cancer can't be removed by surgery and shows on scans.

I have provided a sample of my tumor tissue that has not been treated with radiation.

My side effects from past cancer treatments are mild or gone, except for some hormone issues or mild neuropathy.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive MK-3120 at specified dose levels to evaluate safety and efficacy

Up to approximately 18 months

Follow-up

Participants are monitored for safety and effectiveness after treatment

Up to approximately 54 months

What Are the Treatments Tested in This Trial?

Interventions

• MK-3120

Trial Overview The study is testing the safety and tolerability of MK-3120 in patients with advanced solid tumors. It aims to find out how well participants handle this potential new treatment option for cancers that occur in body organs and tissues.

How Is the Trial Designed?

Group I: Arm 2 Dose level 2 Experimental Treatment 1 Intervention

Participants receive MK-3120 at dose level 2 as per the schedule specified in the arm.

Group II: Arm 1 Dose level 1 Experimental Treatment 1 Intervention

Participants receive MK-3120 at dose level 1 as per the schedule specified in the arm.

Who Is Running the Clinical Trial?

Merck Sharp & Dohme LLC

Lead Sponsor

Trials

4,096

Recruited

5,232,000+

Chirfi Guindo

Merck Sharp & Dohme LLC

Chief Marketing Officer since 2022

Degree in Engineering from Ecole Centrale de Paris, MBA from New York University Stern School of Business

Robert M. Davis

Merck Sharp & Dohme LLC

Chief Executive Officer since 2021

JD from Northwestern University Pritzker School of Law, MBA from Northwestern University Kellogg Graduate School of Management, Bachelor's in Finance from Miami University